Data-mining for sulfur and fluorine: An evaluation of pharmaceuticals to reveal opportunities for drug design and discovery

Journal of Medicinal Chemistry

Volumn 57, Issue 7, 2014, Pages 2832-2842

  Ilardi, Elizabeth A ^a   Vitaku, Edon ^a   Njardarson, Jon T ^a  

^a The University of Arizona   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORGANOFLUORINE DERIVATIVE; ORGANOSULFUR DERIVATIVE;

ARTICLE; CHEMICAL COMPOSITION; COMBINATORIAL CHEMISTRY; DATA MINING; DRUG APPROVAL; DRUG DESIGN; DRUG MARKETING; PRESCRIPTION; QUALITATIVE ANALYSIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; DATA MINING; DRUG APPROVAL; DRUG DESIGN; DRUG DISCOVERY; EVALUATION STUDIES AS TOPIC; FLUORINE; HUMANS; PHARMACEUTICAL PREPARATIONS; SULFUR; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84894601276     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401375q     Document Type: Article

References (72)

1. Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. DrugBank 3.0: A Comprehensive Resource for "Omics" Research on Drugs Nucleic Acids Res. 2011, 39, D1035-D1041
2. Thomson Reuters Integrity. http://integrity.prous.com (2013).
3. About GOSTAR. http://gostardb.com/gostar/doc/HyperlinkDownloadPDF.pdf (accessed August 2013).
4. Ranjan, J. Data Mining in Pharma Sector: Benefits Int. J. Health Care Qual. Assur. 2009, 22, 82-92
5. For a recent example of mining a drug database, see the following: Giordanetto, F.; Kihlberg, J. Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?. J. Med. Chem. [Online early access]. DOI: 10.1021/jm400887j. Published Online: Aug 28, 2013.
6. For a representative example, see the following: Rogers, E.; Araki, H.; Batory, L. A.; McInnis, C. E.; Njardarson, J. T. Highly Selective Copper-Catalyzed Ring Expansion of Vinyl Thiiranes: Application to Synthesis of Biotin and the Heterocyclic Core of Plavix J. Am. Chem. Soc. 2007, 129, 2768-2769
7. Our Top200 drug posters and disease focused pharmaceutical posters (including two additional themes: fluorinated pharmaceuticals and sulfur-containing pharmaceuticals) can be found at the Njardarson research group Web site: http://www.cbc.arizona.edu/njardarson/group/.
8. Ilardi, E. A.; Vitaku, E.; Njardarson, J. T. An In-Pharm-Ative Educational Poster Anthology Highlighting the Therapeutic Agents That Chronicle Our Medicinal History J. Chem. Educ. 2013, 90, 1403-1405
9. Drug Information Online. http://www.drugs.com/ (accessed November 2011).
10. CenterWatch: FDA Approved Drugs. http://centerwatch.com/drug-information/ (2013).
11. Approved Drug Products with Therapeutic Evaluations (Orange Book), 33 rd, ed.; U.S. Department of Health and Human Services, U.S. Food and Drug Administration: Rockville, MD, 2013.
12. Acton, A. Q., Ed. Sulfur Compounds: Advances in Research and Application; ScholarlyEditions: Atlanta, GA, 2012.
13. Emsley, J. Nature's Building Blocks: An A-Z Guide to the Elements; Oxford University Press: Oxford, U.K., 2011.
14. For information regarding the historical medicinal uses of sulfur, see the following: Rapp, G. R. Archaeo-Mineralology; Springer-Verlag: Berlin, Germany, 2009.
15. Data reflecting the top 200 rankings was collected from http://www.pharmacytimes.com/publications/issue/2012/July2012/ Top-200-Drugs-of-2011 (2012).
16. Filler, R.; Saha, R. Fluorine in Medicinal Chemistry: A Century of Progress and a 60-Year Retrospective of Selected Highlights Future Med. Chem. 2009, 1, 771-791
17. For information on the use of biological drugs in the pharmaceutical industry, see the following: Evens, R. P, Ed. Drug and Biological Development: From Molecule to Product and Beyond; Springer Science + Business Media, LLC: New York, NY, 2007.
18. Greenstein, B.; Brook, D. A. Biological Therapeutics; Pharmaceutical Press: London, U.K., 2011.
19. For a recent review of sulfur-containing amino acids in pharmacology, see the following: Cordomi, A.; Gómez-Tamayo, J. -C.; Gigoux, V.; Fourmy, D. Sulfur-Containing Amino Acids in 7TMRs: Molecular Gears for Pharmacology and Function Trends Pharmacol. Sci. 2013, 34, 320-331
20. Müller, K.; Faeh, C.; Diederich, F. Fluorine in Pharmaceuticals: Looking Beyond Intuition Science 2007, 317, 1881-1886
21. Kirk, K. L. Fluorine in Medicinal Chemistry: Recent Therapeutic Applications of Fluorinated Small Molecules J. Fluorine Chem. 2006, 127, 1013-1039
22. Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Fluorine in Medicinal Chemistry Chem. Soc. Rev. 2008, 37, 320-330
23. Hagmann, W. L the Many Roles for Fluorine in Medicinal Chemistry J. Med. Chem. 2008, 51, 4359-4369
24. Ramachandran, P. V. Welcome to "Fluorine in Medicinal Chemistry" Future Med. Chem. 2009, 1, 771-772
25. O'Hagan, D. Fluorine in Health Care: Organofluorine Containing Blockbuster Drugs J. Fluorine Chem. 2010, 131, 1071-1081
26. Ojima, I., Ed. Fluorine in Medicinal Chemistry and Chemical Biology; John Wiley & Sons: Chichester, U.K., 2009.
27. Böhm, H.-J.; Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B.; Müller, K.; Obst-Sander, U.; Stahl, M. Fluorine in Medicinal Chemistry ChemBioChem 2004, 5, 637-643
28. For information regarding structure and function of fluorine in pharmaceuticals, see the following: Bégué, P.; Bonnet-Delpon, D., Eds. Bioorganic and Medicinal Chemistry of Fluorine; John Wiley & Sons, Inc.: Hoboken, NJ, 2008.
29. For information about newly developed fluorinated derivatives, see the following: Manteau, B.; Pazenok, S.; Vors, J.-P.; Leroux, F. R. New Trends in Chemistry of alpha-Fluorinated Ethers, Thioethers, Amines and Phosphines J. Fluorine Chem. 2010, 131, 140-158
30. Representative examples of adverse affects of fluorinated steroids and corticosteroids: Burry, J. N. Topical Drug Addiction, Adverse Effects of Fluorinated Corticosteroid Creams and Ointments Med. J. Aust. 1973, 1, 393-396
31. Kligman, A. M.; Leyden, J. J. Adverse Effects of Fluorinated Steroids Applied to the Face JAMA, J. Am. Med. Assoc. 1974, 60-62
32. Spina, D. Drugs for the Treatment of Pulmonary Diseases. In Biological Interactions of Sulfur Compounds; Mitchell, S., Ed.; Cambridge University Press: Cambridge, U.K., 2003.
33. Oae, S.; Okuyama, T., Eds. Organic Sulfur Chemistry: Biochemical Aspects; CRC Press, Inc.: Boca Raton, FL, 1992.
34. Cremlyn, R. J., Ed. An Introduction to Organosulfur Chemistry; John Wiley & Sons: Chichester, U.K., 1996.
35. 5 moiety is beginning to attract the attention of medicinal chemists the σ/π plot was first published in the following: Craig, P. N. Interdependence between Physical Parameters and Selection of Substituent Groups for Correlation Studies J. Med. Chem. 1971, 14, 680-684
36. 5) Organic Molecules J. Fluorine Chem. 2012, 143, 57-93
37. Gaudillière, J.-P the First Miracle Drugs: How the Sulfa Drugs Transformed Medicine (Review) Bull. Hist. Med. 2009, 83, 218-220
38. Anderson, R.; Groundwater, P.; Todd, A.; Worsley, A. J. Antibacterial Agents: Chemistry, Mode of Action, Mechanisms of Resistance, and Clinical Applications; John Wiley & Sons, Ltd.: Chichester, U.K., 2012.
39. U.S. Food and Drug Administration. Sulfanilamide Disaster. http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/ SulfanilamideDisaster/ (accessed March 2013).
40. Rogers, K., Ed. Medicine and Healers through History; Britannica Educational Publishing: New York, NY, 2011.
41. Rudy, E. Sulfa Allergy" - Distinguishing between Sulfonamide and Sulfite Sensitivities Drug Ther. Top. 2004, 33, 21-26
42. Smith, D. A.; Jones, R. M the Sulfonamide Group as a Structural Alert: A Distorted Story? Curr. Opin. Drug Discovery Dev. 2008, 11, 72-79
43. For more information, see the following: Knowles, S.; Shapiro, L. E.; Shear, N. H. Reactive Metabolites and Adverse Drug Reactions Clin. Rev. Allergy Immunol. 2001, 24, 239-247
44. Shoaib, S.; Shah, A.; Rivera, G.; Ashfaq, M. Recent Advances in Medicinal Chemistry of Sulfonamides. Rational Design as Anti-Tumoral, Anti-Bacterial and Anti-Inflammatory Agents Mini-Rev. Med. Chem. 2013, 13, 70-86
45. For mechanistic studies of sulfa drugs, see the following: Haruki, H.; Pedersen, M. G.; Gorsko, K. I.; Pojer, F.; Johnsson, K. Tetrahydrobiopterin Biosynthesis as an Off-Target of Sulfa Drugs Science 2013, 340, 987-991
46. The medicinal history of β-lactam antibiotics has been extensively reviewed. Hunter, P. A.; Darby, G. K.; Russell, N. J. Fifty Years of Antimicrobials: Past Perspective and Future Trends; Press Syndicate of the University of Cambridge: New York, NY, 1995.
47. Tames, R. Penicillin: A Breakthrough in Medicine; Heinemann Library: Chicago, IL, 2006.
48. Beta-Lactam Antibiotics: Penicillin, Ampicillin, Beta-Lactamase, Amoxicillin, Beta-Lactam Antibiotic, History of Penicillin, Flucloxacillin; General Books LLC, 2010.
49. Greenwood, D.; Finch, R.; Davey, P.; Wilcox, M., Eds. Antimicrobial Chemotherapy, 5 th ed.; Oxford University Press, Inc.: New York, NY, 2007.
50. Duma, R. J. Aztreonam, the First Monobactam Ann. Intern. Med. 1987, 106, 766-767
51. Loughlin, K. R.; Generali, J., Eds. Prescription Drugs: Alternative Uses, Alternative Cures: Over 1,500 New Uses for FDA-Approved Drugs; The Philip Leif Group, Inc.: New York, NY, 2006.
52. Damani, L. A., Ed. Sulphur Containing Drugs and Related Organic Compounds; Ellis Horwood Limited: Chichester, U.K., 1989.
53. For a recent example, see the following: Stamford, A.; Strickland, C. Inhibitors of BACE for Treating Alzheimer's Disease: A Fragment-Based Drug Discovery Story Curr. Opin. Chem. Biol. 2013, 17, 320-328
54. Lücking, U. Sulfoximines: A Neglected Opportunity in Medicinal Chemistry Angew. Chem., Int. Ed. 2013, 52, 9399-9408
55. Welch, J. T.; Lim, D. S the Synthesis and Biological Activity of Pentafluorosulfanyl Analogs of Fluoxetine, Fenfluramine, And Norfenfluramine Bioorg. Med. Chem. 2007, 15, 6659-6666
56. Wipf, P.; Mo, T.; Geib, S. J.; Caridha, D.; Dow, G. S.; Gerena, L.; Roncal, N.; Milner, E. E. Synthesis and Biological Evaluation of the First Pentafluorosulfanyl Analogs of Mefloquine Org. Biomol. Chem. 2009, 7, 4163-4165
57. Acton, A. Q. Advances in Chlorothiazide Research and Application; ScholarlyEditions: Atlanta, GA, 2012.
58. Siddiqui, N.; Ahuja, P.; Ahsan, W.; Pandeya, S. N.; Alam, M. S. Thiadiazoles: Progress Report on Biological Activities J. Chem. Pharm. Res. 2009, 1, 19-30
59. Li, Y.; Geng, J.; Liu, Y.; Yu, S.; Zhao, G. Thiadiazole - A Promising Structure in Medicinal Chemistry ChemMedChem 2013, 8, 27-41
60. Grillo, M. P. Drug- S -acyl-glutathione Thioesters: Synthesis, Bioanalytical Properties, Chemical Reactivity, Biological Formation and Degradation Curr. Drug Metab. 2011, 12, 229-224
61. Golan, D. E.; Tashjian, A. H.; Armstron, E. J.; Armstron, A. W., Eds. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy, 3 rd ed.; Lippincott Williams & Wilkins, a Wolters Kluwer Business: Philadelphia, PA, 2012.
62. Jain, A. K.; Vaidya, A.; Ravichandran, V.; Kashaw, S. K.; Agrawal, R.-K. Recent Developments and Biological Activities of Thiazolidinone Derivatives: A Review Bioorg. Med. Chem. 2012, 20, 3378-3395
63. Levine, R. R.; Walsh, C. T.; Shwartz-Bloom, R. D., Eds. Pharmacology Drug Actions and Reactions, 6 th ed.; Parthenon Publishing Group: New York, NY, 2000.
64. For the most recent World Health Organization Lists of Essential Medicines, see the following: http://www.who.int/medicines/publications/ essentialmedicines/en/ (2013).
65. Walker, M., Ed. DMSO Nature's Healer; Avery: New York, NY, 1993.
66. Jones, C. J.; Thornback, J. R. Medicinal Applications of Coordination Chemistry; The Royal Society of Chemistry: Cambridge, U.K., 2007.
67. Jones, R. N.; Fritsche, T. R.; Sader, H. S.; Ross, J. E. Activity of Retapamulin (SB-275833), a Novel Pleuromutilin, against Selected Resistant Gram-Positive Cocci Antimicrob. Agents Chemother. 2006, 50, 2583-2586
68. Kollef, M. H. New Antimicrobial Agents for Methicillin-Resistant Staphyloccoccus aureus Crit. Care Resusc. 2009, 11, 282-286
69. For information regarding lurasidone, see the following: Caccia, S.; Pasina, L.; Nobili, A. Critical Appraisal of Lurasidone in the Management of Schizophrenia Neuropsychiatr. Dis. Treat. 2012, 8, 155-168
70. Smith, I.; Nathanson, M.; White, P. F. Sevoflurane - A Long-Awaited Volatile Anaesthetic Br. J. Anaesth. 1996, 76, 435-445
71. For medical information regarding Xtandi, see http://xtandihcp.com/ (accessed Jun 2013).
72. For an example of our recent endeavors in sulfur chemistry, see the following: Li, F.; Calabrese, D.; Brichacek, M.; Lin, I.; Njardarson, J. T. Efficient Synthesis of Thiopyrans Using Sulfur-Enabled Anionic Cascade Angew. Chem., Int. Ed. 2012, 51, 1938-1941